Apnimed (NASDAQ:APMD) Rating Increased to Hold at Zacks Research

Zacks Research upgraded shares of Apnimed (NASDAQ:APMD) to a hold rating in a research report report published on Wednesday morning,Zacks.com reports.

Other analysts also recently issued reports about the stock. Bank of America initiated coverage on shares of Apnimed in a report on Tuesday. They issued a “buy” rating and a $41.00 price target for the company. Lifesci Capital assumed coverage on Apnimed in a research report on Tuesday. They issued an “outperform” rating and a $50.00 target price for the company. Evercore assumed coverage on shares of Apnimed in a research note on Tuesday. They set an “outperform” rating for the company. Wall Street Zen upgraded shares of Apnimed to a “hold” rating in a research note on Saturday, August 8th. Finally, Cantor Fitzgerald began coverage on Apnimed in a report on Tuesday. They issued an “overweight” rating and a $60.00 target price on the stock. Four investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, Apnimed presently has a consensus rating of “Moderate Buy” and an average price target of $50.33.

Apnimed Trading Down 2.9%

Shares of NASDAQ:APMD opened at $28.72 on Wednesday. Apnimed has a 52-week low of $16.12 and a 52-week high of $35.29.

Insider Buying and Selling

In other Apnimed news, major shareholder Morningside Venture Investment bought 312,500 shares of Apnimed stock in a transaction on Monday, August 3rd. The shares were purchased at an average cost of $16.00 per share, for a total transaction of $5,000,000.00. Following the completion of the acquisition, the insider owned 7,152,713 shares in the company, valued at approximately $114,443,408. The trade was a 4.57% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website.

About Apnimed

Apnimed Inc is a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies which address the neurobiology of sleep-related breathing diseases. Apnimed Inc is based in CAMBRIDGE, Mass.